TY - JOUR
T1 - Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes
AU - Yoon, Ji Young
AU - Kwon, Hyuck Hoon
AU - Min, Seong Uk
AU - Thiboutot, Diane M.
AU - Suh, Dae Hun
N1 - Funding Information:
This work was supported by grant (04-2005-0430) from the SNUH Research Fund and by grant (A080258) from the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea. JYY and HHK developed the conceptual framework of the study, designed the experiments, conducted studies, analyzed the data, and wrote the paper. SUM conducted studies and analyzed the data. DMT provided cell lines and adviced on in vitro aspects of the study. DHS conceived of and supervised the whole project and wrote the manuscript.
PY - 2013/2
Y1 - 2013/2
N2 - Acne vulgaris is a highly prevalent skin disorder characterized by hyperseborrhea, inflammation, and Propionibacterium acnes overgrowth. Only isotretinoin and hormonal therapy reduce sebum production. To identify a new drug candidate that modulates sebum, we examined the effects of EGCG, the major polyphenol in green tea, on human SEB-1 sebocytes and in patients with acne. In SEB-1 sebocytes, we found that EGCG reduced sebum by modulating the AMPK-SREBP-1 signaling pathway. EGCG also reduces inflammation by suppressing the NF-κB and AP-1 pathways. EGCG also induces cytotoxicity of SEB-1 sebocytes via apoptosis and decreases the viability of P. acnes, thus targeting almost all the pathogenic features of acne. Finally, and most importantly, EGCG significantly improved acne in an 8-week randomized, split-face, clinical trial, and was well tolerated. Our data provide a therapeutic rationale for the use of EGCG in acne.
AB - Acne vulgaris is a highly prevalent skin disorder characterized by hyperseborrhea, inflammation, and Propionibacterium acnes overgrowth. Only isotretinoin and hormonal therapy reduce sebum production. To identify a new drug candidate that modulates sebum, we examined the effects of EGCG, the major polyphenol in green tea, on human SEB-1 sebocytes and in patients with acne. In SEB-1 sebocytes, we found that EGCG reduced sebum by modulating the AMPK-SREBP-1 signaling pathway. EGCG also reduces inflammation by suppressing the NF-κB and AP-1 pathways. EGCG also induces cytotoxicity of SEB-1 sebocytes via apoptosis and decreases the viability of P. acnes, thus targeting almost all the pathogenic features of acne. Finally, and most importantly, EGCG significantly improved acne in an 8-week randomized, split-face, clinical trial, and was well tolerated. Our data provide a therapeutic rationale for the use of EGCG in acne.
UR - http://www.scopus.com/inward/record.url?scp=84872608286&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872608286&partnerID=8YFLogxK
U2 - 10.1038/jid.2012.292
DO - 10.1038/jid.2012.292
M3 - Article
C2 - 23096708
AN - SCOPUS:84872608286
SN - 0022-202X
VL - 133
SP - 429
EP - 440
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
IS - 2
ER -